Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Rickets due to low serum phosphate concentrations, the cause of which can be nutritional or genetic. This condition is characterized by normal parathyroid hormone concentrations, usually caused by renal phosphate wasting occurring in isolation or as part of a renal tubular disorder, and characterized by resistance to treatment with ultraviolet radiation or vitamin D.
Biomarker and diagnostic research for hypophosphatemic rickets has been reported in the published literature.
11 clinical trials registered, 2 recruiting. Interventions under study include drug therapy and other interventions. Pipeline includes 2 PHASE3, 1 PHASE2, 1 PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT06065852](https://clinicaltrials.gov/study/NCT06065852) |
Data assembled from 3 of 12 sources · Last updated Sep 18, 2026, 7:13 PM UTC
National Registry of Rare Kidney Diseases
— |
UK Kidney Association |
RECRUITING |
[NCT03771105](https://clinicaltrials.gov/study/NCT03771105) | The Impact of Phosphate Metabolism on Healthy Aging | EARLY_PHASE1 | Yale University | RECRUITING |
201 publications have been identified in PubMed for hypophosphatemic rickets. Research spans Review / Meta-Analysis (24%), Epidemiology / Natural History (22%), and Case Report / Case Series (22%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 45 | 24% |
Disease patterns and progression | 42 | 22% |
Patient case studies | 41 | 22% |
Laboratory research | 28 | 15% |
Clinical study results | 16 | 9% |
Testing and diagnosis research | 7 | 4% |
Other research | 5 | 3% |
New treatment approaches | 3 | 2% |
Galal S (2026). [PMID: 42081159](https://pubmed.ncbi.nlm.nih.gov/42081159/). *Arch Orthop Trauma Surg*. [Epidemiology / Natural History]
Kumar S (2026). [PMID: 41558912](https://pubmed.ncbi.nlm.nih.gov/41558912/). *Pathology*. [Review / Meta-Analysis]
Munteanu M (2026). [PMID: 41176198](https://pubmed.ncbi.nlm.nih.gov/41176198/). *Bone*. [Case Report / Case Series]
Mitchell D (2026). [PMID: 41137448](https://pubmed.ncbi.nlm.nih.gov/41137448/). *J Clin Endocrinol Metab*. [Clinical Trial Publication]
Kandemir T (2026). [PMID: 41711038](https://pubmed.ncbi.nlm.nih.gov/41711038/). *J Clin Res Pediatr Endocrinol*. [Review / Meta-Analysis]
Lemoine S (2026). [PMID: 40852855](https://pubmed.ncbi.nlm.nih.gov/40852855/). *J Clin Endocrinol Metab*. [Basic Science / Preclinical]
Gan Z (2026). [PMID: 42001164](https://pubmed.ncbi.nlm.nih.gov/42001164/). *Orphanet J Rare Dis*. [Basic Science / Preclinical]
Bruno I (2026). [PMID: 41770448](https://pubmed.ncbi.nlm.nih.gov/41770448/). *J Endocrinol Invest*. [Review / Meta-Analysis]
Sawalha NA (2026). [PMID: 41820620](https://pubmed.ncbi.nlm.nih.gov/41820620/). *Calcif Tissue Int*. [Clinical Trial Publication]
Krishnamurthy S (2026). [PMID: 41741919](https://pubmed.ncbi.nlm.nih.gov/41741919/). *Indian J Pediatr*. [Review / Meta-Analysis]
AI-curated news mentioning hypophosphatemic rickets
Updated May 19, 2026
BioMarin's Phase 3 trial for its investigational therapy in ENPP1 deficiency failed to show clinical improvements, missing key secondary endpoints related to rickets severity and growth. This setback raises concerns about the future of their rare disease portfolio.